[O3] Oral Session 3　Hematologic Malignancies
【E】

[O3-4] Outcomes from ZUMA-5 (Axicabtagene Ciloleucel) vs SCHOLAR-5 Control in Relapsed/Refractory Follicular Lymphoma (R/R FL)

^○Anik R Patel¹, M Lia Palomba², Paola Ghione^2,3, Kevin Deighton⁴, Caron A Jacobson⁵, Myrna Nahas³, Scott Jung³, Anthony Hatswell⁴, Steve Kanters⁶, Eve Limbrick-Oldfield⁶, Sally W Wade⁷, Julia Thornton Snider³, Sattva S Neelapu⁸, Maria Teresa Riberio⁹, John Gribben¹⁰, John Radford¹¹, Sabela Bobillo¹², Herve Ghesquieres¹³ (1.Kite, a Gilead Company, Santa Monica, CA, USA, 2.Memorial Sloan Kettering Cancer Center, New York, NY, USA, 3.Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA, 4.Delta Hat, Nottingham, UK, 5.Dana-Farber Cancer Institute, Boston, MA, USA, 6.RainCity Analytics, Vancouver, BC, Canada, 7.Wade Outcomes Research and Consulting, Salt Lake City, UT, USA, 8.The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 9.Portuguese Oncology Institute of Porto, Porto, Portugal, 10.Cancer Research UK Barts Centre, London, UK, 11.The Christie NHS Foundation Trust and University of Manchester, Manchester, UK, 12.Vall D’Hebron Institute of Oncology, Barcelona, Spain, 13.Centre Hospitalier Lyon Sud, Lyon, France)